Clinical trial
Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism
NCT00465751 · University Hospital, Basel, Switzerland, Other · Completed
Key facts
| NCT number | NCT00465751 |
|---|---|
| Title | Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism |
| Official title | Effects of Activation of the Farnesoid X Receptor (FXR) on Hepatic Lipid and Glucose Metabolism in Patients With the Metabolic Syndrome and Familial Forms of Hypertriglyceridemia |
| Lead sponsor | University Hospital, Basel, Switzerland, Other |
| Status | Completed |
| Phase | Early Phase 1 |
| Study type | Interventional |
| Conditions | Metabolic Syndrome, Familial Hypertriglyceridemia, Familial Combined Hyperlipidemia |
| Intervention type | Drug |
| Interventions | chenodeoxycholic acid, placebo capsules |
| Enrollment | 30 |
| Start date | Oct 1, 2004 |
| First posted | Apr 25, 2007 |
| Last update posted | Mar 9, 2012 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: